Nebius Group TodayNBISNebius Group$46.74 +0.70 (+1.51%) 52-Week Range$14.09▼$55.75Price Target$66.50Add to WatchlistThe search for the next impactful name in artificial intelligence (AI) often leads investors to crowded fields. Yet, quietly capturing a significant market share is Nebius Group N.V. NASDAQ: NBIS. This international AI cloud provider delivered a staggering 385% year-over-year revenue growth in its latest quarter.Get NVIDIA alerts:This narrative of rapid expansion becomes even more compelling ...

Key Takeaways FTK has posted ten consecutive quarters of improved adjusted EBITDA, a rare feat in oilfield services. Q1 2025 adjusted EBITDA jumped 93% year over year as profit margins rose and SG Flotek forecasts 80% EBITDA growth for 2025, fueled by new contracts and international chemistry sales.Flotek Industries (FTK) is quietly heading toward a milestone: 10 straight quarters of improved adjusted EBITDA. This kind of consistent performance is rare for a smaller energy company. From losing $5.1 millio ...

Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial result ...

Core Insights - The company provides an updated outlook for Q2 2025, with expectations subject to finalization of results to be published on July 31, 2025 [1] Integrated Gas - Adjusted EBITDA production is expected to be between 900 - 940 kboe/d, down from 927 kboe/d in Q1 2025 [2] - LNG liquefaction volumes are projected to be between 6.4 - 6.8 million tonnes, slightly lower than 6.6 million tonnes in Q1 2025 [2] - Underlying operating expenses (opex) are expected to remain stable at 1.0 - 1.2 billion [2] - The taxation charge is anticipated to decrease to between 0.3 - 0.6 billion from 0.8 billion in Q1 2025 [2] Upstream - Production is forecasted to decline to between 1,660 - 1,760 kboe/d, down from 1,855 kboe/d in Q1 2025, due to scheduled maintenance and the sale of SPDC in Nigeria [4] - Underlying opex is expected to range from 1.9 - 2.5 billion [4] - The taxation charge is projected to decrease to between 1.6 - 2.4 billion from 2.6 billion in Q1 2025 [4] - Joint ventures and associates are expected to contribute approximately 0.2 billion in profit/loss, with exploration well write-offs estimated at 0.2 billion [4] Marketing - Sales volumes are expected to be between 2,600 - 3,000 kb/d, down from 2,674 kb/d in Q1 2025 [5] - Underlying opex is projected to be between 2.3 - 2.7 billion [5] - The taxation charge is expected to decrease to between 0.2 - 0.6 billion from 0.4 billion in Q1 2025 [5] - Adjusted earnings are anticipated to be higher than Q1 2025 [6] Chemicals and Products - The indicative refining margin is expected to increase to $8.9/bbl from $6.2/bbl in Q1 2025 [8][14] - The indicative chemicals margin is projected to rise to $166/tonne from $126/tonne in Q1 2025, although adjusted earnings are expected to be a loss [8][14] - Refinery utilization is expected to improve to between 92% - 96% from 85% in Q1 2025, while chemicals utilization is expected to decline to between 68% - 72% due to unplanned maintenance [8] Renewables and Energy Solutions - Adjusted earnings are expected to range from (0.4) - 0.2 billion, indicating a potential loss [9] Corporate - Adjusted earnings are projected to be between (0.6) - (0.4) billion, slightly worse than (0.5) billion in Q1 2025 [10] Shell Group - Cash flow from operations (CFFO) is expected to see tax payments between 2.8 - 3.6 billion, slightly lower than 2.9 billion in Q1 2025 [11] - Working capital movements are projected to range from (1) - 4 billion, compared to (2.7) billion in Q1 2025 [11] Guidance and Consensus - The company will publish consensus managed by Vara Research on July 23, 2025 [13]

Investor and Analyst Day June 3, 2025 1 Welcome and Agenda Allison Wey SVP, Investor Relations and Corporate Communications Copyright © 2021 -2025 Xeris Pharmaceuticals, Inc. All rights reserved . 2 Important Disclosures Forward-LookingStatements and Other Information Any statements in presentation other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma H ...

4Q & FY 2016 Earnings FEBRUARY 14, 2017 FORWARD LOOKING STATEMENTS CAESARS ENTERTAINMENT CORPORATION USE OF NON-GAAP MEASURES The following non-GAAP measures will be used in the presentation and discussed on the conference call which this presentation accompanies: Definitions of these non-GAAP measures, reconciliations to their nearest GAAP measures, and the reasons management believes these measures provide useful information for investors, can be found on Slide 4 and in the Appendix to this presentation, ...

4Q and FY 2018 Earnings • February 21, 2019 CAESARS ENTERTAINMENT CORPORATION 1 Forward Looking Statements Certain information in this presentation and discussed on the conference call which this presentation accompanies constitutes forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts and by the use of words such as "will," "may," "expect," "project ...

Greatness Starts Here We transform organizations by building exceptional leaders, teams, and cultures that get results. © FranklinCovey Co. All rights reserved. PROPRIETARY AND CONFIDENTIAL INVESTOR UPDATE Third Quarter Fiscal 2025 Forward-Looking Statements/Non-GAAP This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon management's current expectations and are subject to various risks and u ...

-Trinity Biotech projects it reached Adjusted EBITDA -positive operations during Q2 2025 and expects to be Adjusted EBITDA positive going forward, reflecting continued strong execution on its comprehensive transformation plan.- - The Company now expects to be meaningfully Adjusted EBITDA -positive and cashflow positive from ongoing operating activities, starting Q3 2025 and into the foreseeable future.- DUBLIN, July 01, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechn ...

NEW YORK, July 1, 2025 /PRNewswire/ -- IQSTEL Inc. (NASDAQ: IQST), a rapidly expanding multinational leader in telecommunications and emerging technologies, is pleased to announce that the previously disclosed acquisition of 51% of GlobeTopper (GlobeTopper.com) is now officially closed and effective as of July 1, 2025. This milestone marks a major acceleration of IQSTEL's global fintech expansion strategy and positions the company to further solidify its path toward $1 billion in annual revenue by 2027. --- ...